Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study
Objective: To use clinical and biological data from PPMI to estimate sample size for disease modification studies in de novo PD Background: One barrier to…Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)
Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…Exergaming in Patients with Parkinson’s Disease
Objective: To analyze the effects of exergaming on functional balance and fatigue in patients with Parkinson's disease Background: Interventions that promote the integration of multi-sensory,…Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study
Objective: To review symptomatic therapy (ST) utilization trends in individuals with early Parkinson’s disease (PD). Background: There are changing trends in ST utilization in early…Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study
Objective: To determine the longitudinal change in the Movement Disorder Society –Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) in Parkinson’s disease (PD) participants who were untreated…Preliminary Report on the MAESTRO Study: A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease.
Objective: To report enrollment and tolerability data of mirabegron treatment in PD patients with OAB. Background: Lower urinary tract symptoms in PD have an estimated…The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…Programming of deep brain stimulators in Parkinson’s disease with early motor complications (EARLYSTIM-study)
Objective: Recently the EARLYSTIM study showed the superior effect of subthalamic stimulation to best medical treatment in Parkinson`s disease with early motor complications. Background: EARLYSTIM…Innovative recruitment strategies accelerate enrollment of genetic mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI)
Objective: Determine feasibility of digital recruitment strategies, centralized screening, and a dedicated referral coordinator to enroll participants with LRRK2 or GBA mutations into PPMI, a…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.